Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematological Malignancy, Autoimmune & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LYN/JTK8 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LYN Recombinant Kinase (Active) – Full-length or Kinase Domain, GST/His-tagged. High Purity (>95%), Endotoxin <1 EU/μg, Sequence Verified, HEK293 Expressed for authentic phosphorylation. | View LYN Products |
| Mutant Panel | LYN Resistance Mutants (gatekeeper and activation loop variants) – Custom mutant panel for resistance profiling, including somatic and pathogenic gain-of-function mutations. Theoretical MW verified by mass spec. | View LYN Products |
| Gene Delivery | LYN Promise-ORF / Lentivirus Premade Particles – Full-length wild-type and mutant ORF for stable cell line construction (BaF3, 293T). | View LYN Products |
| Benchmark Ab | Anti-LYN Recombinant Rabbit mAb – Sequence‑verified detection reagent for assay development (IP/Western/IHC). | View LYN Products |
| Validator | LYN siRNA Set – For specific knockdown and target engagement verification in cellular assays. | View LYN Products |
| Related Target: BTK | BTK (Bruton's Tyrosine Kinase) – Parallel BCR pathway target; primary comparator for combination strategies. | View BTK Products |
| Related Target: SYK | SYK (Spleen Tyrosine Kinase) – Upstream BCR signaling partner; synergy and bypass studies. | View SYK Products |
| Related Target: SRC | SRC Kinase – Src family prototype; critical off‑target for selectivity screening. | View SRC Products |
| Related Target: FYN | FYN Kinase – Src family member; T‑cell and B‑cell signaling comparator. | View FYN Products |
| Related Target: CSF1R | CSF1R (Colony Stimulating Factor 1 Receptor) – Macrophage signaling; LYN‑mediated oncogenic pathway component. | View CSF1R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Active vs. Inactive Conformational Purity | Purified LYN kinase domain (WT/mutant) with SH3/SH2 domain intact; theoretical MW confirmed by SDS‑PAGE and SEC; endotoxin controlled for cellular kinase assays. |
| Src‑Family Selectivity (High Homology to SRC, FYN, LCK, HCK, BLK) | Human SFK homolog panel strictly sequence‑verified by mass spectrometry; >95% purity; ATP‑binding site mutants for selectivity validation. |
| Drug Resistance Profiling | Clinically relevant mutations available (e.g., somatic mutation in breast pleomorphic lobular carcinoma; two pathogenic SAIDV mutations that increase activity via loss of autoinhibition). |
| Cellular Target Engagement & Phosphorylation Validation | High‑specificity siRNA for orthogonal validation; lentivirus for stable overexpression in suspension cells; compatible with flow cytometry and Western blot. |
| False Positives / Assay Specificity | Sequence‑verified LYN siRNA included for target‑specificity controls; recombinant benchmark antibodies included for assay standardization. |
Live LYN/JTK8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
"The race for LYN/JTK8-targeted therapeutics is intensifying, with the field bifurcating between repurposed pan-SFK inhibitors in oncology and next-generation selective LYN inhibitors for autoimmune indications." As first-generation multi-kinase agents (e.g., dasatinib, bosutinib classes) establish clinical proof-of-mechanism in CML and ALL, the next wave of R&D is targeting highly selective LYN inhibition and targeted degraders (PROTACs) to overcome off‑target toxicity and acquired resistance. LYN function is mediated through its SH3, SH2, and protein kinase domains (UniProt P07948), and clinically relevant mutations—including a somatic mutation in breast pleomorphic lobular carcinoma and two pathogenic mutations in SAIDV that increase kinase activity due to loss of autoinhibition—highlight the need for isoform‑specific and mutant‑selective approaches.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pan‑SFK / Multi‑Kinase Inhibitors | Established oncology portfolios (e.g., dasatinib, bosutinib classes) | CML, ALL, solid tumors | Selectivity assay: Need WT vs mutant LYN plus SFK homolog panel. |
| Selective LYN Small Molecules | Autoimmune & inflammation biotechs | SLE, RA, B‑cell mediated disease | Conformational kinase assay: Need high‑purity active/inactive LYN protein. |
| PROTAC / Targeted Degrader | Emerging TPD biotechs | Hematologic malignancies, B‑cell malignancies | Binary/ternary complex formation: Need full‑length LYN and E3 ligase components. |
| Combination Therapy | Various (BMS, Pfizer) | Solid tumors (breast, prostate) | Pathway mapping: Need related target reagents (BTK, SYK, SRC). |